Charlotte Näslund-Koch1, Børge G Nordestgaard1, Stig E Bojesen2. 1. All authors: Herlev and Gentofte Hospital, Copenhagen University Hospital, and University of Copenhagen, Denmark. 2. All authors: Herlev and Gentofte Hospital, Copenhagen University Hospital, and University of Copenhagen, Denmark. stig.egil.bojesen@regionh.dk.
Abstract
PURPOSE: CHEK2 is a cell cycle checkpoint regulator, and the CHEK2*1100delC germline mutation leads to loss of function and increased breast cancer risk. It seems plausible that this mutation could also predispose to other cancers. Therefore, we tested the hypothesis that CHEK2*1100delC heterozygosity is associated with increased risk for other cancers in addition to breast cancer in the general population. PATIENTS AND METHODS: We examined 86,975 individuals from the Copenhagen General Population Study, recruited from 2003 through 2010. The participants completed a questionnaire on health and lifestyle, were examined physically, had blood drawn for DNA extraction, were tested for presence of CHEK2*1100delC using Taqman assays and sequencing, and were linked over 1943 through 2011 to the Danish Cancer Registry. Incidences and risks of individual cancer types, including breast cancer, were calculated using Kaplan-Meier estimates, Fine and Gray competing-risks regressions, and stratified analyses with interaction tests. RESULTS: Among 86,975 individuals, 670 (0.8%) were CHEK2*1100delC heterozygous, 2,442 developed breast cancer, and 6,635 developed other cancers. The age- and sex-adjusted hazard ratio for CHEK2*1100delC heterozygotes compared with noncarriers was 2.08 (95% CI, 1.51 to 2.85) for breast cancer and 1.45 (95% CI, 1.15 to 1.82) for other cancers. When stratifying for sex, the age-adjusted hazard ratios for other cancers were 1.54 (95% CI, 1.08 to 2.18) for women and 1.37 (95% CI, 1.01 to 1.85) for men (sex difference: P = .63). For CHEK2*1100delC heterozygotes compared with noncarriers, the age- and sex-adjusted hazard ratios were 5.76 (95% CI, 2.12 to 15.6) for stomach cancer, 3.61 (95% CI, 1.33 to 9.79) for kidney cancer, 3.45 (95% CI, 1.09 to 10.9) for sarcoma, and 1.60 (95% CI, 1.00 to 2.56) for prostate cancer. CONCLUSION: CHEK2*1100delC heterozygosity is associated with 15% to 82% increased risk for at least some cancers in addition to breast cancer. This information may be useful in clinical counseling of patients with this loss-of-function mutation.
PURPOSE:CHEK2 is a cell cycle checkpoint regulator, and the CHEK2*1100delC germline mutation leads to loss of function and increased breast cancer risk. It seems plausible that this mutation could also predispose to other cancers. Therefore, we tested the hypothesis that CHEK2*1100delC heterozygosity is associated with increased risk for other cancers in addition to breast cancer in the general population. PATIENTS AND METHODS: We examined 86,975 individuals from the Copenhagen General Population Study, recruited from 2003 through 2010. The participants completed a questionnaire on health and lifestyle, were examined physically, had blood drawn for DNA extraction, were tested for presence of CHEK2*1100delC using Taqman assays and sequencing, and were linked over 1943 through 2011 to the Danish Cancer Registry. Incidences and risks of individual cancer types, including breast cancer, were calculated using Kaplan-Meier estimates, Fine and Gray competing-risks regressions, and stratified analyses with interaction tests. RESULTS: Among 86,975 individuals, 670 (0.8%) were CHEK2*1100delC heterozygous, 2,442 developed breast cancer, and 6,635 developed other cancers. The age- and sex-adjusted hazard ratio for CHEK2*1100delC heterozygotes compared with noncarriers was 2.08 (95% CI, 1.51 to 2.85) for breast cancer and 1.45 (95% CI, 1.15 to 1.82) for other cancers. When stratifying for sex, the age-adjusted hazard ratios for other cancers were 1.54 (95% CI, 1.08 to 2.18) for women and 1.37 (95% CI, 1.01 to 1.85) for men (sex difference: P = .63). For CHEK2*1100delC heterozygotes compared with noncarriers, the age- and sex-adjusted hazard ratios were 5.76 (95% CI, 2.12 to 15.6) for stomach cancer, 3.61 (95% CI, 1.33 to 9.79) for kidney cancer, 3.45 (95% CI, 1.09 to 10.9) for sarcoma, and 1.60 (95% CI, 1.00 to 2.56) for prostate cancer. CONCLUSION:CHEK2*1100delC heterozygosity is associated with 15% to 82% increased risk for at least some cancers in addition to breast cancer. This information may be useful in clinical counseling of patients with this loss-of-function mutation.
Authors: Heather H Cheng; Nola Klemfuss; Bruce Montgomery; Celestia S Higano; Michael T Schweizer; Elahe A Mostaghel; Lisa G McFerrin; Evan Y Yu; Peter S Nelson; Colin C Pritchard Journal: Prostate Date: 2016-06-21 Impact factor: 4.104
Authors: Maria I Carlo; Semanti Mukherjee; Diana Mandelker; Joseph Vijai; Yelena Kemel; Liying Zhang; Andrea Knezevic; Sujata Patil; Ozge Ceyhan-Birsoy; Kuo-Cheng Huang; Almedina Redzematovic; Devyn T Coskey; Carolyn Stewart; Nisha Pradhan; Angela G Arnold; A Ari Hakimi; Ying-Bei Chen; Jonathan A Coleman; David M Hyman; Marc Ladanyi; Karen A Cadoo; Michael F Walsh; Zsofia K Stadler; Chung-Han Lee; Darren R Feldman; Martin H Voss; Mark Robson; Robert J Motzer; Kenneth Offit Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: Thorunn Rafnar; Gudbjorg R Sigurjonsdottir; Simon N Stacey; Gisli Halldorsson; Patrick Sulem; Luba M Pardo; Hannes Helgason; Stefan T Sigurdsson; Thorkell Gudjonsson; Laufey Tryggvadottir; Gudridur H Olafsdottir; Jon G Jonasson; Kristin Alexiusdottir; Asgeir Sigurdsson; Julius Gudmundsson; Jona Saemundsdottir; Jon K Sigurdsson; Hrefna Johannsdottir; Andre Uitterlinden; Sita H Vermeulen; Tessel E Galesloot; Dawn C Allain; Martin Lacko; Bardur Sigurgeirsson; Kristin Thorisdottir; Oskar T Johannsson; Fridbjorn Sigurdsson; Gunnar B Ragnarsson; Helgi Isaksson; Hronn Hardardottir; Tomas Gudbjartsson; Daniel F Gudbjartsson; Gisli Masson; Lambertus A M L Kiemeney; Amanda Ewart Toland; Tamar Nijsten; Wilbert H M Peters; Jon H Olafsson; Steinn Jonsson; Unnur Thorsteinsdottir; Gudmar Thorleifsson; Kari Stefansson Journal: J Natl Cancer Inst Date: 2018-09-01 Impact factor: 13.506
Authors: Siddhartha Yadav; Steven N Hart; Chunling Hu; David Hillman; Kun Y Lee; Rohan Gnanaolivu; Jie Na; Eric C Polley; Fergus J Couch; Manish Kohli Journal: JCO Precis Oncol Date: 2019-09-17
Authors: Jung Kim; Nicholas Light; Vallijah Subasri; Erin L Young; Talia Wegman-Ostrosky; Donald A Barkauskas; David Hall; Philip J Lupo; Rajesh Patidar; Luke D Maese; Kristine Jones; Mingyi Wang; Sean V Tavtigian; Dongjing Wu; Adam Shlien; Frank Telfer; Anna Goldenberg; Stephen X Skapek; Jun S Wei; Xinyu Wen; Daniel Catchpoole; Douglas S Hawkins; Joshua D Schiffman; Javed Khan; David Malkin; Douglas R Stewart Journal: JCO Precis Oncol Date: 2021-01-11